TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01583062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Description: Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin plus placebo
Description: Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
Study: NCT01188031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG
Description: A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Description: B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
Study: NCT01269216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU with leucovorin
Description: 5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TS-1 with Irinotecan
Description: Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
Study: NCT03596996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with identical appearance comparison intervention arm
Study: NCT02263404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: DBS Implant Stimulation
Study: NCT02043795

Intervention type: DEVICE
Group type: OTHER
Intervention: BVS, Abbott Vascular
Description: The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
Study: NCT02546375

Intervention type: DRUG
Intervention: Bosutinib
Description: Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
Study: NCT01339260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant and Palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant and Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study: NCT03478215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Stem Cells (MSCs) Infusion
Description: Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.~Mesenchymal Stromal Stem Cells Infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo) Infusion
Description: Matching infusion containing normal saline wrapped to cover contents to maintain the blind.~Normal Saline (Placebo) Infusion.
Study: NCT01303172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-101
Description: IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol.
Study: NCT00937274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T4 phage cocktail test
Description: T4 phages 106 PFU/ ml up to 5 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial T4 phage cocktail
Description: Treatment as recommended by the manufacturer (Microgen phages)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard oral rehydration solution (ORS)
Description: Standard hospital treatment with ORS
Study: NCT02913183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: young Fresh Frozen Plasma
Description: Blood plasma from healthy male donors aged 18-30 years old.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: old Fresh Frozen Plasma
Description: Blood plasma from healthy male donors aged 40-55 years old.
Study: NCT02458144

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total hip arthroplasty
Description: The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total hip arthroplasty
Description: The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed.
Study: NCT03495531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality headset with calming scenery
Study: NCT00725153

Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lenses (PureVision)
Description: Commercially marketed, soft contact lenses worn bilaterally for 10 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lenses (PureVision)
Description: Commercially marketed, soft contact lenses worn bilaterally for 10 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses (Acuvue2)
Description: Commercially marketed, soft contact lenses worn bilaterally for 10 hours

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses (Acuvue2)
Description: Commercially marketed, soft contact lenses worn bilaterally for 10 hours
Study: NCT00618644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injection
Study: NCT04102267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome injectable suspension
Description: Liposomal bupivacaine 266 mg via injection
Study: NCT04313803

Intervention type: DEVICE
Intervention: CGM
Description: Dexcom CGM system

Intervention type: DEVICE
Intervention: CGM
Description: Dexcom CGM system

Intervention type: DEVICE
Intervention: CGM
Description: Dexcom CGM system
Study: NCT03755453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aid: Phonak Audéo B90-Direct
Description: Hearing aids will be fitted to the participants individual hearing loss.
Study: NCT04102267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl without epinephrine via continuous infusion
Description: Bupivacaine HCl 300 mg via continuous infusion
Study: NCT00212550

Intervention type: PROCEDURE
Intervention: Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.
Description: Sputum induction
Study: NCT03254745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist led pharmaceutical care
Description: The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
Study: NCT03755453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid: Phonak Audéo B90-Direct
Description: Hearing aids will be fitted to the participants individual hearing loss.
Study: NCT03487250

Intervention type: DEVICE
Intervention: TenJet System
Description: Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
Study: NCT03386123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Insomnia
Description: Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
Study: NCT01677468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermediate embolization
Description: TACE with substasis using gelfoam

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete embolization
Description: TACE with complete embolization using gelfoam
Study: NCT00264719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide (Maxolon)
Description: Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide (Maxolon)
Description: Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 10 mg
Study: NCT01414946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition with glucose and amino acids
Description: Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
Study: NCT00264719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 10 mg
Study: NCT01414946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous nutrition with amino acids
Description: Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient's measured resting energy expenditure.
Study: NCT03386123

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Audiological Care
Description: Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Support Group
Description: Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
Study: NCT06305572

Intervention type: DIAGNOSTIC_TEST
Intervention: QFR
Description: Patients suspected with CAD undergoing diagnostic coronary angiography with an indication for to perform invasive FFR were included. QFR was analyzed in an independent core laboratory (Uijeongbu Eulji Medical Center) using the software package QAngio XA 3D 2.1 (Medis Medical Imaging Systems, Leiden, the Netherlands).
Study: NCT05323526

Intervention type: DIAGNOSTIC_TEST
Intervention: Catquest-9SF questionnaire
Description: Patients complete the questionnaire preoperatively and postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Demographics and clinical parameters
Description: The following clinical parameters are evaluated: age, gender, ocular and systemic comorbidities, educational level, preoperative and postoperative monocular distance uncorrected visual acuity (UVA), distance best spectacle-corrected visual acuity (BSCVA) of the eye for cataract surgery, binocular distance UVA and BSCVA, refraction, spherical equivalent (SE), and intraocular pressure.
Study: NCT04537962

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Periogard® mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Periogard® mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Periogard® mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Peroxyl® mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Peroxyl® mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Peroxyl® mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Total® Mouthwash
Description: Patients will be submitted to antisepsia of the oral mucosa with Colgate Total® Mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste with sodium monofluorophosphate
Description: Patients will be submitted to brushing with toothpaste with sodium monofluorophosphate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste with sodium fluoride and zinc
Description: Patients will be submitted to brushing with toothpaste with sodium fluoride and zinc

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste with tin fluoride
Description: Patients will be submitted to brushing with toothpaste with tin fluoride
Study: NCT04748744

Intervention type: COMBINATION_PRODUCT
Intervention: Butyrylcholinesterase
Description: Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases
Study: NCT03926091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel chemotherapy (injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel chemotherapy (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)
Study: NCT01694862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated FP/PNC service delivery
Description: The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
Study: NCT03684629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the response of KPI and corresponding suggestion
Description: Standardized templates of medical record, evidence-based clinical pathway, and written care protocols are applied in all hospitals.The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. Feedback system of performance measures: the hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Expert online consultation: based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
Study: NCT01604330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
Study: NCT02266069

Intervention type: OTHER
Group type: OTHER
Intervention: Care Pathway for Primary Palliative Care
Description: Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.

Intervention type: OTHER
Group type: OTHER
Intervention: Care Pathway for Primary Palliative Care
Description: Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.

Intervention type: OTHER
Group type: OTHER
Intervention: Care Pathway for Primary Palliative Care
Description: Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.

Intervention type: OTHER
Group type: OTHER
Intervention: Care Pathway for Primary Palliative Care
Description: Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.

Intervention type: OTHER
Group type: OTHER
Intervention: Care Pathway for Primary Palliative Care
Description: Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
Study: NCT01913600

Intervention type: DEVICE
Group type: OTHER
Intervention: Resolute Integrity Stent
Description: Drug eluting stent (DES)
Study: NCT00793468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 once daily for 12 weeks
Study: NCT04382781

Intervention type: DRUG
Intervention: NO-Immunosuppressive
Description: Patients not receiving immunosuppressive drugs

Intervention type: DRUG
Intervention: Immunosuppressive
Description: Patients receiving immunosuppressive drugs (overall, and specific drugs)

Intervention type: DRUG
Intervention: Immunoglubulins
Description: Patients receiving immunoglubulins
Study: NCT04497480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System
Description: The Passive, Motor-Assisted and Active Resistive Upper/Lower Extremities Rehabilitation Training System is designed for patients conﬁned to bed at the long-term care facilities hospitals, in early rehabilitation. This system can induce a natural movements of the upper/lower limb with safe motorized passive movement, as well as motor-assisted and active resistive muscle training to stimulate nerves, increase blood circulation of aﬀected tissue, cell metabolism and improve joint mobility, in promoting upper/lower extremities motor recovery.
Study: NCT01319097

Intervention type: OTHER
Group type: OTHER
Intervention: Sorbion Sachet S
Description: Dressing is indicated for moderately to heavily exuding wounds.
Study: NCT01892995

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Study: NCT03898167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Recall
Description: Participants receive a scripted telephone recall from a trained patient navigator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Recall
Description: Participants receive a scripted telephone recall from a trained patient navigator.
Study: NCT04283578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT
Description: One group will receive OT for 4 weeks, then placebo or OT for 8 weeks
Study: NCT03898167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Recall
Description: Participants receive a scripted telephone recall from a trained patient navigator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed HPV Self-Sampling Kit
Description: Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.